TLR9 and colitis: The same group went on to show that intestinal inflammation following DSS challenge is reduced in TLR9−/− mice compared with wild-type and that administration of adenoviral ODNs (which blocks the effects of DNA sequences) to wild-type mice with established colitis results in amelioration of disease (264).